GRAND CAYMAN, CAYMAN ISLANDS, Silexion Therapeutics Corp. (NASDAQ: SLXN) (Silexion or the Firm), a clinical-stage biotech creating RNA interference (RNAi) therapies for KRAS-driven cancers, immediately introduced that the Firm’s administration will probably be attending and presenting on the Noble Capital Markets 20th Annual Rising Progress Fairness Convention going down December 3-4, 2024, in Boca Raton, Florida.
Ilan Hadar, Chief Govt Officer will ship an organization presentation titled Remodeling Most cancers Care: Silexion Therapeutics’ Progressive Method to Pancreatic Most cancers on December 4, 2024 at 11:30 am. A replay of the presentation will probably be posted, when out there, to Silexion’s web site on the Presentation & Occasions web page of the buyers part.
The Firm’s administration staff will probably be out there for one-on-one conferences all through the summit. buyers are inspired to contact the Noble investor outreach staff to schedule a gathering.
About Silexion Therapuetics
Silexion Therapeutics (NASDAQ: SLXN) is a pioneering clinical-stage, oncology-focused biotechnology firm creating progressive RNA interference (RNAi) therapies to deal with strong tumors pushed by KRAS mutations, the most typical oncogenic driver in human cancers. The corporate’s first-generation product, LODER™, has proven promising leads to a Section 2 trial for non-resectable pancreatic most cancers. Silexion can be advancing its next-generation siRNA candidate, SIL-204, designed to focus on a broader vary of KRAS mutations and exhibiting important potential in preclinical research. The corporate stays dedicated to pushing the boundaries of therapeutic innovation in oncology, with a concentrate on enhancing outcomes for sufferers with difficult-to-treat cancers. For extra info please go to: https://silexion.com
Firm Contact
Silexion Therapeutics Corp
Ms. Mirit Horenshtein Hadar, CFO
[email protected]
Investor Contact
ARX | Capital Markets Advisors
North American Equities Desk
[email protected]